Within months after publishing of NINDS results, the European Union also published the results of ECASS I study where a higher dose of tPA (1.1 mg/kg) was administered to AIS patients within 0–6 h of stroke onset (18). This evidence concerns the gene PLAT and androgen insensitivity syndrome.